5The National Institute of Neurological Disorders and Stroke tt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333(24): 1581-1587.
6Verstraete M. Thrombolysis: An approach still on the move. Drugs,1989, 37(2): 116-122.
7Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).JAMA, 1995, 274(13): 1017-1025.
8Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (E CASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet, 1998, 352(9136): 1245-1251.
9Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA, 2000,283(9): 1145-1150.
10Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 1999, 282(21): 2019-2026.
